Austrália - inglês - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - bosentan monohydrate, quantity: 64.5 mg (equivalent: bosentan, qty 62.5 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - bosentan monohydrate, quantity: 64.5 mg (equivalent: bosentan, qty 62.5 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - paracetamol, quantity: 500 mg; codeine phosphate hemihydrate, quantity: 8 mg - tablet, uncoated - excipient ingredients: erythrosine aluminium lake; lactose monohydrate; magnesium stearate; potato starch; povidone; docusate sodium; colloidal anhydrous silica - for the temporary relief of acute moderate pain in patients over the age of 12 years

África do Sul - inglês - South African Health Products Regulatory Authority (SAHPRA)

cipla medpro (pty) ltd - injection - see ingredients - each vial contains docetaxel 20,0 mg

África do Sul - inglês - South African Health Products Regulatory Authority (SAHPRA)

cipla medpro (pty) ltd - injection - see ingredients - each 5,0 ml vial contains docetaxel 80,0 mg

África do Sul - inglês - South African Health Products Regulatory Authority (SAHPRA)

cipla medpro (pty) ltd - injection - see ingredients - each 5,0 ml solution contains doxorubicin hydrochloride 10,0 mg

África do Sul - inglês - South African Health Products Regulatory Authority (SAHPRA)

cipla medpro (pty) ltd - injection - see ingredients - each 25,0 ml solution contains doxorubicin hydrochloride 50,0 mg

África do Sul - inglês - South African Health Products Regulatory Authority (SAHPRA)

cipla medpro (pty) ltd - injection - see ingredients - each vial contains bleomycin sulphate 7,5 mg

Quênia - inglês - Pharmacy and Poisons Board

cipla ltd cipla house, peninsula business park, ganpatrao - paracetamol ph. eur. - effervescent tablet - 1000 mg - non-opioid analgesics andantipyretics: anilides

Quênia - inglês - Pharmacy and Poisons Board

cipla ltd cipla house, peninsula business park, ganpatrao - paracetamol bp - effervescent tablet - 500 mg - non-opioid analgesics andantipyretics: anilides